Table 1.
Baseline characteristics of included studies and participants.
| Author | Year | Number of patients, ZES/EES, n | Mean age, ZES/EES, mean (SD or IQR) | Male, ZES/EES, % | Patient population | Intervention subtype | DAPT use | Follow‐up |
|---|---|---|---|---|---|---|---|---|
| Ploumen et al. | 2022 | 1173/1172 | 63.6 (10.9)/64.0 (10.7) | 72.3/72.1 | Patients presenting with any coronary syndrome could participate, and any type of lesion (e.g., de novo, restenotic, or coronary bypass lesion) was permitted |
Synergy EES Resolute Integrity ZES |
ZES = 43EES = 37 | 5 years |
| Youn et al. | 2020 | 639/638 | 64.0 ± 11.3/65.6 ± 11.0 | 67.1/66.1 | Patients with stable coronary artery disease or ACS including ST‐segment–elevation MI were eligible if at least 1 coronary artery had significant stenosis. |
Xience EES Resolute ZES |
ZES = 596EES = 590 | 2 years |
| Buiten et al. | 2019 | 1173/1172 | 63·6 ± 10·9/64·0 ± 10·7 | 72.3/72.1 | All coronary syndromes, de novo andrestenotic lesions, and coronary or bypass lesions were permitted |
Very‐thin strut platinum‐chromium Synergy EUSdurable‐polymer thin‐strut cobalt chromium Resolute Integrity ZES |
NR | 3 years |
| Kim et al. | 2019 | 1252/2503 | 60.78 ± 9.68/63.1 ± 10.8 | 65.6/69.8 | Major exclusion criteria were severe left ventricular systolic dysfunction, cardiogenic shock, symptomatic heart failure, and an increased risk of bleeding |
Platinum Chromium EUS Cobalt Chromium ZES |
ZES = 37 EES = 55 | 3 years |
| Kang et al. | 2019 | 153/149 | 65.8 ± 8.6/65.9 ± 10.0 | 75.2/73.2 | Patients with very long coronary artery disease of diameter stenosis of at least 50% and visual lesion length of atleast 50 mm who planned to implant at least two DES were enrolled in the study. Exclusion criteria included acute ST‐segment MI necessitating primary PCI | Resolute R‐ZES Xience EES | All patients on DAPT for at least 12 months | 13 months |
| Zocca et al. | 2018 | 906/905 | 63.9 ± 10.6/63.9 ± 11.0 | 73.4/72.6 | Patients with an indication for PCI (all coronary syndromes, de novo and restenotic lesions, and coronary artery or bypass stenosis were permitted) | ZES (cobalt chromium‐based Resolute Integrity) EES (platinum chromium‐based PROMUS Element) | ZES = 262 EES = 259 | 5 years |
| Kok et al. | 2018 | 1173/1172 | 63.6 ± 10.9/64.0 ± 10.7 | 72.3/72.1 | All coronary syndromes, de novo and restenotic lesions, and coronary or bypass lesions were permitted. There was no limit for lesion length, reference vessel size, and number of lesions or vessels to be treated | Platinum‐chromium EES (SYNERGY), new generation thin‐strut ZES (Resolute Integrity) | ZES = 103 EES = 87 | 2 years |
| von Birgelen et al. | 2016 | 1173/1172 | 63.6 ± 10.9/64.0 ± 10.7 | 72.3/72.1 | Patients presenting with any coronary syndrome could participate, and any type of lesion (e.g., de novo, restenotic, or coronary bypass lesion) was permitted | Platinum‐chromium EES (SYNERGY), new generation thin‐strut ZES (Resolute Integrity) | All patients on DAPT for 6‐12 months | 1 year |
| Sen et al. | 2015 | 906/905 | 63.9 ± 10.6/63.9 ± 11.0 | 73.4/72.6 | Patients aged 18 years and older who required a PCI with implantation of a DES were recruited | Resolute Integrity ZES Promus Element EES | ZES = 262 EES = 259 | 2 years |
| Lin et al. | 2015 | 248/249 | 62 (55–71)/65 (57–72) | 73.79/74.3 | Patients were eligible if they had at least one coronary lesion with stenosis of more than 50% in a vessel with a reference diameter of 2.25 to 4.0 mm. | ZES, Abbott EES, Medtronic | Clopidogrel for 12 months | 15 months |
| Taniwaki et al. | 2014 | 1122/1124 | 64.4 ± 10.9/64.2 ± 10.8 | 76.7/77.2 | Patients with stable CAD or acute coronary syndromes requiring revascularization | Resolute‐ZES (Medtronic, Minneapolis, Minnesota) and XIENCE V EES (Abbott Vascular, Abbott Park, Illinois) | ZES = 124 EES = 121 | 4 years |
| Park et al. | 2014 | 2,503/1,252 | 63.5 ± 10.7/63.1 ± 10.8 | 65.6/69.8 | Trial participants were 18 years of age or older and had at least one clinically significant stenotic lesion amenable to PCI in the coronary artery, venous or arterial bypass grafts | platinum‐chromium EES; cobalt‐chromium ZES | Patients were randomized to TAT or DDAT | 1 year |
| Lowik et al. | 2014 | 692/689 | 63.9 ± 10.9/64.5 ± 1 10.7 | 72.5/72.6 | Patients with stable angina or non‐ST‐elevation acute coronary syndromes | Second‐Generation Zotarolimus‐Eluting Resolute and Everolimus‐Eluting Xience V Stents | NR | 3 years |
| Tandjung et al. | 2013 | 697/694 | 63.9 ± 10.9/64.5 ± 10.7 | 72.5/72.6 | Indication for percutaneous coronary intervention (PCI) with DES | Second‐Generation Zotarolimus‐Eluting Resolute and Everolimus‐Eluting Xience V Stents | All patients on 12 months DAPT | 2 years |
| von Birgelen et al. | 2013 | 905/905 | 64 (56–72)/65 (57–72) | 73/73 | Patients aged 18 years and older who required a PCI with implantation of a DES were recruited |
Resolute Integrity ZES Promus Element EES |
ZES = 262 EES = 259 | 1 year |
| Mehilli et al. | 2013 | 324/326 | 69.4 ± 10.4/70.2 ± 9.4 | 72.8/77.3 | Patients older than 18 years of age with ischemic symptoms or evidence of myocardial ischemia in the presence of 50% de novo stenosis located in the left main stem | Resolute ZES (Medtronic Cardiovascular, Santa Rosa, California) Xience V EES (Abbott Vascu‐lar Devices, Santa Clara, California) | clopidogrel 75 mg/day or prasugrel 10 mg/day for at least 12 months Aspirin indefinitely | 1 year |
| von Birgelen et al. | 2012 | 697/694 | 63.9 ± 10.9/64.5 ± 10.7 | 72.5/72.6 | Acute ST‐segment elevation myocardial infarctions not eligible | Resolute ZES (Medtronic Cardiovascular, Santa Rosa, California) Xience V EES (Abbott Vascular Devices, Santa Clara, California) | NR | |
| Serruys et al. | 2010 | 1140/1152 | 64.4 ± 10.9/64.2 ± 10.8 | 76.7/77.2 | Patients with chronic, stable coronary artery disease or acute coronary syndromes, including myocardial infarction with or without ST‐segment elevation | Resolute ZES (Medtronic CardioVascular) EES (Xience V, Abbott Vascular Devices) | All patients on 75 mg of acetylsalicylic acid indefinitely 75 mg of clopidogrel for 6 months | 13 months |
Note: Number of patients who received ZES = 7782. Number of patients who received EES = 6537. Weighted average of mean age ZES/EES = 64.1 ± 9.9/65 ± 10.0. Weighted average (%) of male population ZES/EES = 72.1/73.4.
Abbreviations: CAD, coronary artery disease; DES, drug eluting stents; EES, Everolimus‐eluting stent; IQR, Interquartile range; n, number; NR, not reported; PCI, percutaneous coronary intervention; SD, standard deviation; ZES, Zotarolimus‐eluting stent.